Update on the use of memantine in Alzheimer's disease

Area of Science:

• Neuroscience
• Pharmacology
• Geriatrics

Background:

• Alzheimer's disease (AD) is a progressive neurodegenerative disorder.
• N-methyl-D-aspartate receptor (NMDAR) antagonists, like memantine, are explored for AD treatment.
• Current AD therapies offer limited symptomatic relief.

Purpose of the Study:

• To review the pharmacodynamics and pharmacokinetics of memantine.
• To evaluate the efficacy and safety of memantine in Alzheimer's disease patients.
• To analyze memantine's effects based on disease severity and combination therapy.

Main Methods:

• Review of 7 randomized controlled trials (RCTs) and post-hoc analyses.
• Analysis of studies stratified by Alzheimer's disease severity (MMSE scores).
• Inclusion of studies evaluating memantine as monotherapy and in combination with donepezil.

Main Results:

• Memantine demonstrated statistically significant but clinically small benefits in cognition, global functioning, ADL, and neuropsychiatric symptoms for moderate to severe AD (MMSE <14).
• No significant effects were observed in mild to moderate AD (MMSE 14-24) with memantine monotherapy.
• Combination therapy with donepezil showed positive effects in mild to moderate AD patients.
• Side effects were generally mild and comparable to placebo.

Conclusions:

• Memantine may provide modest benefits for patients with moderate to severe Alzheimer's disease.
• Efficacy in mild to moderate AD is less evident, though combination therapy shows promise.
• Further research is needed to clarify memantine's role and cost-effectiveness in Alzheimer's disease management.